Islam Zaydan
Neurology · Pittsburgh, PANPI 1083731202
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,768 of the $3,136 with a category attached, or 88.3%. Hoffmann-la Roche Limited accounts for 83.4% of it on its own, with 2 other manufacturers making up the rest.
Across 6 payments — averaging $522.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$3K
- Bristol Myers Squibb$401
- AstraZeneca$120
Across 86 payments — averaging $11,315 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$409K
- F. Hoffmann-la Roche AG$241K
- Genentech, Inc.$217K
- Novartis$77K
- Bristol Myers Squibb$20K
- AstraZeneca$9K
What the payments were for
- Travel & lodging$2,76888%
- Food & beverage$36812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 4 | $2,615 |
| Bristol Myers Squibb | 1 | $401 |
| AstraZeneca | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$2,603
How this compares
$3,136 in reported general payments places this provider in the 65th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 19 | $842 |
| Pyridostigmine Bromide | 15 | $806 |
| Memantine Hcl | 15 | $738 |
| Levetiracetam | 35 | $567 |
| MethotrexateMethotrexate Sodium | 21 | $291 |
| Topiramate | 25 | $202 |
| Cyclobenzaprine Hcl | 12 | $97 |
Paid to pharmacies, not to this prescriber.
Other neurology in Pittsburgh
- Anoopum GuptaPittsburgh$592K
- Thomas ScottPittsburgh$476K
- James ValerianoPittsburgh$416K
- Amber van LaarPittsburgh$413K
- Andrea SynowiecPittsburgh$386K
- Dolores Dominguez SantamariaPittsburgh$265K
- Heather MouryPittsburgh$186K
- Troy DesaiPittsburgh$174K
- Richard KasdanPittsburgh$172K
- David LobasPittsburgh$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.